Mirtazapine in Alzheimer-associated Weight Loss

Mirtazapine in Alzheimer-associated Weight Loss: a Retrospective Phase IV Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01505504

Enrollment

Registered

2012-01-06

Start date

2004-01-31

Completion date

2011-12-31

Last updated

2012-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease, Dementia, Mixed Dementia, Weight Loss

Brief summary

Weight loss is a frequent problem associated with Alzheimers disease (AD). Mirtazapine has weight loss as a frequent side effect. The aim of this retrospective study is to check whether mirtazapine 30 mg (once daily) can counteract weight loss in patients with AD or mixed dementia (AD + vascular).

Interventions

DRUGmirtazapine

30 mg at bedtime

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* AD or mixed dementia * documented weight loss * mirtazapine 30 mg explicitly prescribed against weight loss

Exclusion criteria

* no treatment compliance * other causes of weight loss * other interventions against weight loss

Design outcomes

Primary

Measure	Time frame
body weight	6 months

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026